Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare changes in HIV levels and certain immune cells among patients at different stages of HIV infection. This study will also see how a combination of stavudine (d4T), lamivudine (3TC), indinavir (IDV), and nelfinavir (NFV) affects these levels.

Current findings in anti-HIV drug treatment have led to a greater understanding of the background of HIV. To find the best anti-HIV treatment to eliminate all HIV viruses, cells and tissues infected with the HIV virus are examined after combination anti-HIV treatment, when the level of HIV infection is low. The ERADICATE study will examine the idea that HIV viruses can be eliminated at any stage of infection over time.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Indinavir; Lamivudine; Nelfinavir; Stavudine

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Are infected with HIV and have had certain tests to indicate the stage of their disease.

• Are at least 18 years old.

• Practice birth control during the study.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Have received anti-HIV medication for more than 1 week.

• Have a serious AIDS-related infection or other illness.

• Require medication that interferes with the study drugs.

• Have had a peripheral neuropathy, a painful condition affecting the nervous system.

• Have been given drugs that affect the immune system within 2 weeks before study entry.

• Have a bleeding disorder including hemophilia.

• Abuse alcohol or substances.

• Are pregnant or breast-feeding.